Clinical Trials on Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

Total 4461 results

Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
University of Ulm

Terminated

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Germany
National Cancer Institute (NCI)

Completed

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Assisi Foundation

Completed

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

Leukemia, Myeloid, Acute | Myelodysplastic Syndrome | T-cell Lymphoblastic Lymphoma | Leukemia, Lymphocytic, Acute, T-Cell | Juvenile Myelomonocytic Leukemia Lymphoblastic

United States
Masonic Cancer Center, University of Minnesota
University of Minnesota

Withdrawn

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Treatment-Related Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia... and other conditions

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
The First Affiliated Hospital of Soochow University

Unknown

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation (DFMBHSCT)

Higher-risk Myelodysplastic Syndrome | Relapsed /Refractory Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission

United States
National Cancer Institute (NCI)

Active, not recruiting

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
St. Petersburg State Pavlov Medical University

Recruiting

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloid Leukemia, Acute

Russian Federation
Grupo Espanol de trasplantes hematopoyeticos y...

Completed

Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT (BUFLU)

Acute Myeloid Leukemia | Myeloproliferative Disorders | Chronic Myeloid Leukemia | Myelodysplastic Syndrome
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myeloblastic Leukemia | Malignant Lymphoma | Biphenotypic Acute Leukemia

Russian Federation
Haukeland University Hospital

Not yet recruiting

A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients (HUVAMER)

Acute Myeloid Leukemia, Adult | Myelodysplastic Syndromes, Adult

Norway
Zeinab Albadry Mohammed Zahran

Completed

SRSF2 Gene Mutation in Patients With t-MDS/AML

Therapy Related Myelodysplastic Syndrome and Therapy Related Acute Myeloid Leukemia

Egypt
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
Nohla Therapeutics, Inc.
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
Hackensack Meridian Health

Terminated

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)

Acute Myeloid Leukemia and Myelodysplastic Syndrome

United States
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Familial Acute Myeloid Leukemia

Italy
Hackensack Meridian Health

Terminated

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI)

Myeloproliferative Disorders | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloid Malignancies

United States
Merck Sharp & Dohme LLC

Completed

Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) (TALL)

Myelodysplastic Syndrome | Leukemia, Acute Myeloid
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Myelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative Neoplasms

United States
Emory University

No longer available

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
University of Leeds

Completed

Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia

Leukemia

United Kingdom
University of Chicago
National Cancer Institute (NCI)

Completed

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Oncoceutics, Inc.

Recruiting

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Baylor Research Institute

Completed

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Vastra Gotaland Region
Karolinska University Hospital; Sahlgrenska University Hospital, Sweden; Nordic...

Unknown

A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)

Leukemia, Myelomonocytic, Chronic

Sweden
Novartis Pharmaceuticals

Recruiting

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Spain, Italy, Czechia, Malaysia, Turkey, China, United States, Greece, Brazil
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

China
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)

Chronic Myeloid Leukemia

France
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center

Active, not recruiting

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute... and other conditions

United States
City of Hope Medical Center

Terminated

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
University of Ulm

Recruiting

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project (AMLSG BiO)

Acute Myeloid Leukemia (AML) | Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)

Austria, Germany
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

Polycythemia Vera | Chronic Myelomonocytic Leukemia | Hypereosinophilic Syndrome | Chronic Myeloid Leukemia | Mastocytosis

United States
Masonic Cancer Center, University of Minnesota

Completed

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Myeloproliferative Neoplasm

United States
St. Jude Children's Research Hospital
Assisi Foundation

Completed

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Non-Hodgkin's Lymphoma | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia

United States
University of Chicago

Terminated

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States

Clinical Trials on Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations